Corcept Therapeutics (CORT) Scheduled to Post Earnings on Thursday

Corcept Therapeutics (NASDAQ:CORT) is scheduled to release its earnings data after the market closes on Thursday, February 22nd. Analysts expect Corcept Therapeutics to post earnings of $0.18 per share for the quarter.

Corcept Therapeutics (NASDAQ CORT) opened at $15.98 on Tuesday. Corcept Therapeutics has a 52 week low of $8.14 and a 52 week high of $25.96. The company has a market capitalization of $1,823.70, a P/E ratio of 55.11 and a beta of 1.68.

A number of brokerages have commented on CORT. Piper Jaffray Companies set a $30.00 target price on Corcept Therapeutics and gave the company a “buy” rating in a research note on Monday, February 5th. BidaskClub downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 13th. Stifel Nicolaus decreased their target price on Corcept Therapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, February 5th. Finally, Zacks Investment Research downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $21.00.

In other news, insider Robert S. Fishman sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $18.67, for a total transaction of $149,360.00. Following the completion of the transaction, the insider now directly owns 8,000 shares in the company, valued at $149,360. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 24,000 shares of company stock valued at $415,920. Insiders own 19.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Corcept Therapeutics (CORT) Scheduled to Post Earnings on Thursday” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Earnings History for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply